LiqTech International (LIQT) vs Niki BioSolutions (NIKI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Niki BioSolutions (NIKI) has outperformed LiqTech International (LIQT) over the past year, losing 83.1% versus a loss of 84.8%. Over five years, NIKI leads with a -98.5% price change compared with -99.1% for LIQT. LiqTech International is the larger company by market cap ($13.4 million vs $12.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LIQT | NIKI |
|---|---|---|
| Share price | $0.408 | $4.00 |
| Market cap | $13.44M | $12.47M |
| 1-day change | -9.35% | -7.41% |
| YTD return | -72.05% | -62.26% |
| 1-year return | -84.78% | -83.12% |
| 5-year return | -99.14% | -98.46% |
| EPS (TTM) | $-0.74 | $-2.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.35 | $17.60 |
| 52-week low | $0.408 | $4.00 |
| Distance from 52-week high | -87.82% | -77.27% |
| Analyst consensus | none | — |
| Avg. price target upside | +218.63% | — |
| Average volume | 264.13K | 160.00K |
| Shares outstanding | 32.95M | 2.94M |
| Employees | 92 | 1 |
| Sector | Technology | Industrials |
| Industry | Industrial Machinery/Components | Industrial Machinery/Components |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: LiqTech International in Technology and Niki BioSolutions in Industrials.
About LiqTech International
LIQT stock →LiqTech International, Inc., together with its subsidiaries, engages in the design, development, production, marketing, and sale of automated filtering solutions and systems in the Americas, the Asia-Pacific, Europe, the Middle East, and Africa. It operates through three segments: Systems and Aftermarket; Filters and Membranes; and Components.
Technology · Industrial Machinery/Components · 92 employees
About Niki BioSolutions
NIKI stock →Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.
Industrials · Industrial Machinery/Components · 1 employees
LIQT vs NIKI FAQ
Which is bigger, LiqTech International or Niki BioSolutions?
LiqTech International (LIQT) is larger, with a market capitalization of $13.44M compared with $12.47M for Niki BioSolutions (NIKI).
Which stock has performed better over the past year, LIQT or NIKI?
NIKI returned -83.12% over the past 12 months, compared with -84.78% for LIQT (price return, excluding dividends). Past performance does not predict future results.
Are LiqTech International and Niki BioSolutions in the same industry?
Yes. Both are classified in the Industrial Machinery/Components industry within the Technology sector.